Karo Pharma Aktiebolag has completed the previously announced acquisition of the skin health brand, E45®, from Reckitt for a total consideration of GBP 200m. All conditions to the completion of the transaction have been satisfied.
Net sales of E45® was GBP 43m in 2021 and the transaction contributes positively to Karo's market position within skin health, particularly in the UK, South Africa and Spain.
"E45 is a unique brand, which is trusted by consumers and represents quality and consistency, and we see compelling opportunities to unlock value and develop the brand via focused activation and a deepened e-commerce presence. We look forward to engaging with our business partners, customers, and consumers to further develop the brand," says Christoffer Lorenzen, CEO.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!